2-(3-(6-amino-8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9H-purin-9-yl)propyl)isoindoline-1,3-dione | 1333155-96-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 2-(3-(6-amino-8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9H-purin-9-yl)propyl)isoindoline-1,3-dione
• 英文别名: 2-[3-[6-Amino-8-[(6-iodo-1,3-benzodioxol-5-yl)sulfanyl]purin-9-yl]propyl]isoindole-1,3-dione
• CAS: 1333155-96-6
• 化学式: C₂₃H₁₇IN₆O₄S
• 分子量: 600.396
• InChiKey: PROJLSGNKDEMRB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  35
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  151
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  2-(3-(6-amino-8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9H-purin-9-yl)propyl)isoindoline-1,3-dione 在 一水合肼 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 以64%的产率得到9-(3-aminopropyl)-8-((6-iodobenzo[d][1,3]dioxol-5-yl)thio)-9H-purin-6-amine
  参考文献：
  名称：

  Synthesis of purine-scaffold fluorescent probes for heat shock protein 90 with use in flow cytometry and fluorescence microscopy

  摘要：

  Fluorescent ligands for the heat shock protein 90 (Hsp90) were synthesized containing either fluorescein isothiocyanate (FITC), 4-nitrobenzo[1,2,5] oxadiazole (NBD) or the red shifted dye sulforhodamine 101 (Texas Red) conjugated to PU-H71. Two of the compounds, PU-H71-FITC2 (9) and PU-H71-NBD1 (8), were shown to be suitable for fluorescence-activated flow cytometry and fluorescence microscopy. Thus these molecules serve as useful probes for studying Hsp90 in heterogeneous live cell populations. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.07.026
• 作为产物：
  描述：

  8-(6-iodo-benzo[1,3]dioxol-5-ylsulfanyl)adenine 、 N-(3-溴丙基)苯二胺 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 以34%的产率得到2-(3-(6-amino-8-(6-iodobenzo[d][1,3]dioxol-5-ylthio)-9H-purin-9-yl)propyl)isoindoline-1,3-dione
  参考文献：
  名称：

  USES OF LABELED HSP90 INHIBITORS

  摘要：

  公开号：

  EP3208615B1

文献信息

• SELECTIVE GRP94 INHIBITORS AND USES THEREOF
  申请人：Memorial Sloan-Kettering Cancer Center

  公开号：US20160194328A1

  公开（公告）日：2016-07-07

  The disclosure relates to novel selective Grp94 inhibitors, compositions comprising an effective amount of such compounds, and methods to treat or prevent a condition, such as cancer, comprising administering to an animal in need thereof an effective amount of such compounds.

  本公开涉及新型选择性Grp94抑制剂，包括含有有效量此类化合物的组合物，以及治疗或预防疾病的方法，例如癌症，包括向需要此类化合物的动物施用有效量此类化合物。
• Selective Grp94 inhibitors and uses thereof
  申请人：Memorial Sloan-Kettering Cancer Center

  公开号：US10421758B2

  公开（公告）日：2019-09-24

  The disclosure relates to novel selective Grp94 inhibitors, compositions comprising an effective amount of such compounds, and methods to treat or prevent a condition, such as cancer, comprising administering to an animal in need thereof an effective amount of such compounds.

  本公开涉及新型选择性 Grp94 抑制剂、包含有效量此类化合物的组合物，以及治疗或预防癌症等疾病的方法，包括向有需要的动物施用有效量的此类化合物。
• [EN] USES OF LABELED HSP90 INHIBITORS<br/>[FR] UTILISATIONS D'INHIBITEURS MARQUÉS DE HSP90
  申请人：SLOAN KETTERING INST CANCER

  公开号：WO2013009655A3

  公开（公告）日：2013-05-10
• Experimental and Structural Testing Module to Analyze Paralogue-Specificity and Affinity in the Hsp90 Inhibitors Series
  作者：Tony Taldone、Pallav D. Patel、Maulik Patel、Hardik J. Patel、Christopher E. Evans、Anna Rodina、Stefan Ochiana、Smit K. Shah、Mohammad Uddin、Daniel Gewirth、Gabriela Chiosis

  DOI：10.1021/jm400619b

  日期：2013.9.12

  We here describe the first reported comprehensive analysis of Hsp90 paralogue affinity and selectivity, in the clinical Hsp90 inhibitor chemotypes. This has been possible through the development of a versatile experimental assay based on a new FP-probe (16a) that we both describe here. The assay can test rapidly and accurately the binding affinity of all major Hsp90 chemotypes and has a testing range that spans low nanomolar to millimolar binding affinities. We couple this assay with a computational analysis that allows for rationalization of paralogue selectivity and defines not only the major binding modes that relay pan-paralogue binding or, conversely, paralogue selectivity, but also identifies molecular characteristics that impart such features. The Methods developed here provide a blueprint for parsing out the contribution of the four Hsp90 paralogues to the perceived biological activity with the current Hsp90 chemotypes and set the development of paralogue selective inhibitors.
• US9555137B2
  申请人：——

  公开号：US9555137B2

  公开（公告）日：2017-01-31